Current Status of Medication Compliance in Secondary Prevention for Ischemic Stroke or Transient Ischemic Attack

doi:10.3969/j.issn.1673-5765.2018.07.010

Abstract

Abstract:

Objective To investigate the status of medication compliance in secondary prevention for ischemic stroke (IS) or transient ischemic attack (TIA). Methods From June 2012 to January 2013, 25 018 patients with acute ischemic stroke (AIS) or TIA were admitted in the China National Stroke Registry II (CNSR II). The data of patients’ demographics, clinical features and medications use in secondary prevention at 3, 6 and 12 months were collected. Medication persistence at 3, 6 and 12 months was defined as continuation of prescribed medications from discharge to every follow-up point. According to the drug compliance at 12 months, these patients were divided into compliance and noncompliance groups. The factor feature of both groups were compared, and multifactor analysis was conducted to identify the influence factors of drug compliance. Results 16 489 patients who completed 1-year follow-up were analyzed. The rate of secondary prevention medications compliance at 3, 6 and 12 months were 47.0%, 44.5% and 34.9%, respectively. Drugs compliance at 12 months after discharge as follows: the best compliance was diabetes drugs (63.86%), followed by antihypertensive drugs (61.9%), antiplatelet drugs (57.58%), warfarin (44.92%), and statins (24.36%). Multi-factor analysis showed that elder age, female, history of diabetes mellitus, and TIA of cerebrovascular events were influence factors of poor compliance to secondary prevention drugs treatment, while patients with history of stroke had better compliance to secondary prevention drugs. Conclusion The compliance of secondary prevention medications within 12 months in patients with IS and TIA were relatively low, and declined gradually over time.

Key words: Ischemic stroke; Transient ischemic attack; Medication compliance

摘要：

目的评估中国急性缺血性卒中和短暂性脑缺血发作（transient ischemic attack，TIA）患者二级预防药物依从性的现状。

方法中国国家卒中登记研究Ⅱ（China National Stroke Registry，CNSR Ⅱ）2012年6月-2013年1月连续入组急性缺血性卒中和TIA的住院患者25 018例，收集患者人口学信息、临床特点及用药信息等资料，统计患者发病后3个月、6个月及12个月的药物依从性。按照随访12个月时患者二级预防药物依从性分为依从组和非依从组，比较两组患者的各因素特点，并对影响因素进行多因素分析。

结果 16 489例急性缺血性卒中和TIA患者完成12个月的随访。缺血性卒中二级预防药物总体依从性 3个月、6个月、12个月分别为47.0%、44.5%和34.9%。出院12个月时二级预防药物依从性最好的为降糖药（63.86%），之后分别为降压药（61.9%）、抗血小板药（57.58%）、华法林（44.92%）和他汀类药物（24.36%）。二级预防药物依从性多因素分析结果显示：高龄、女性、既往糖尿病史、本次发病为TIA是卒中二级预防药物依从性偏低的影响因素，而既往有卒中病史的患者药物依从性相对较好。

结论中国急性缺血性卒中和TIA患者二级预防药物总体依从性仍偏低，且随时间的延长逐渐下降。

关键词: 缺血性卒中; 短暂性脑缺血发作; 二级预防; 药物依从性

CHEN Yan-Xue, JIANG Yue, LI Zi-Xiao, PAN Yue-Song, JI Rui-Jun, WANG Yi-Long, WANG Yong-Jun, WANG Chen. Current Status of Medication Compliance in Secondary Prevention for Ischemic Stroke or Transient Ischemic Attack[J]. Chinese Journal of Stroke, 2018, 13(07): 686-691.

陈艳雪, 姜悦, 李子孝, 潘岳松, 冀瑞俊, 王伊龙, 王拥军, 王晨. 中国急性缺血性卒中及短暂性脑缺血发作二级预防药物依从性的现状[J]. 中国卒中杂志, 2018, 13(07): 686-691.

References

[1] YANG G，WANG Y，ZENG Y，et al. Rapid health

transition in China，1990-2010：findings from the

Global Burden of Disease Study 2010[J]. Lancet，

2013，381（9882）：1987-2015.

[2] FORD E S，AJANI U A，CROFT J B，et a1.

Explaining the decrease in US deaths from coronary

disease，1980-2000[J]. N Engl J Med，2007，356

（23）：2388-2398.

[3] AHO K，HARMSEN P，HATANO S，et al.

Cerebrovascular disease in the community：results

of a WHO collaborative study[J]. Bull World Health

Organ，1980，58（1）：113-130.

[4] 中华人民共和国国家卫生健康委员会. 中国卫生和

计划生育统计年鉴2017年[EB/OL]. http：//nianjian.

xiaze.com/down/2018/zgwshjhsytjnj-2017.html，

[2018-1-9]（2018-02-07）.

[5] BUSHNELL CD，OLSON DM，ZHAO X，et al.

Secondary preventive medication persistence and

adherence 1 year after stroke[J]. Neurology，2011，77

（12）：1182-1190.

[6] IVEY F M，RYAN A S，HAFER-MACKO C E，et

al. High prevalence of abnorrnal glucose metabolism

and poor sensitivity of fasting plasma glucose in the

chronic phase of stroke[J]. Cerebrovasc Dis，2006，

22（5-6）：368-371.

[7] JIA Q，ZHAO X，WANG C，et al. Diabetes and

poor outcomes within 6 months after acute ischemic

stroke：the China National Stroke Registry[J]. Stroke，

2011，42（10）：2758-2762.

[8] MATZ K，KERESZTES K，TATSCHL C，et al.

Disorders of glucose metabo1ism in acute stroke

patients：an underrecognized problem[J]. Diabetes Care，2006，29（4）：792-797.

[9] LEE M，SAVER J L，LIAO H W，et al. Pioglitazone

for Secondary Stroke Prevention: A Systematic

Review and Meta-Analysis[J]. Stroke，2017，48（2）：

388-393.

[10] WANG Y，CUI L，JI X，et al. The China

National Stroke Registry for patients with acute

cerebrovascular events：design，rationale，and

baseline patient characteristics[J]. Int J Stroke，2011，

6（4）：355-361.

[11] OSTERGAARD K，HALLAS J，BAK S，et al.

Long-term use of antiplatelet drugs by stroke patients：

a follow-up study based on prescription register

data[J]. Eur J Clin Pharmacol，2012，68（12)：1631-

1637.

[1]	CAO Liming, REN Lijie. Progress and Prospects of Diagnosis and Treatment Techniques for Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2024, 19(9): 983-989.
[2]	FU Pengcheng, CAO Liming, ZHU Jiaqian, ZHAO Guiyu, XU Gelin. Research Progress of Reperfusion Therapy for Large Artery Atherosclerotic Ischemic Stroke [J]. Chinese Journal of Stroke, 2024, 19(9): 1004-1011.
[3]	ZHANG Liping, CAO Liming, XIAO Nan, LIAO Yuqi, CHI Feng, YU Yanni, REN Lijie. Research Progress and Challenges of Nanomaterials in the Diagnosis and Treatment of Ischemic Stroke [J]. Chinese Journal of Stroke, 2024, 19(9): 1012-1017.
[4]	WANG Xiaorui, LUO Song, ZOU Liangyu, QU Hongdang, CUI Xue, ZHAO Yujie. Value of Eosinophil-to-Monocyte Ratio in Predicting the Prognosis of Patients with Acute Ischemic Stroke Receiving Intravenous Thrombolysis [J]. Chinese Journal of Stroke, 2024, 19(9): 1025-1033.
[5]	ZHONG Ya’nan, YOU Xuemei, DI Haili, MENG Lin, SUN Lingling. The Value of Serum Cathepsin L Level Combined with ABCD³-I Score in Predicting the Short-Term of Cerebral Infarction of TIA Patients [J]. Chinese Journal of Stroke, 2024, 19(9): 1034-1039.
[6]	WANG Shuo, YU Ping, ZHANG Ning, WANG Chunxue. Bibliometric Analysis of References on the Correlation between Ischemic Stroke and Sleep from 2013 to 2023 [J]. Chinese Journal of Stroke, 2024, 19(9): 1040-1047.
[7]	ZHOU Hongyu, LI Zixiao, WANG Yongjun. Research Progress on Radiomics-Based Brain Age Prediction and Ischemic Stroke [J]. Chinese Journal of Stroke, 2024, 19(9): 1066-1076.
[8]	ABULANIYAZI Anaguli, WU Xiaoxin, LI Jiaoxing, LI Zhuhao, SHENG Wenli. Research Progress on Factors Related to the Susceptibility Vessel Sign and its Clinical Application in Acute Ischemic Stroke [J]. Chinese Journal of Stroke, 2024, 19(9): 1077-1085.
[9]	WU Chunyan, YIN Yashi, WANG Guangzhi, YUE Kuitao. Evaluation and Application of Medical Imaging for Acute Ischemic Stroke at Different Time Windows: A Review [J]. Chinese Journal of Stroke, 2024, 19(9): 1094-1101.
[10]	ZHANG Mengruo, XU Shouchen, SUI Cuicui, LI Yukui, WANG Xueli. The Effects of Lower Limb Rehabilitation Robot Combined with Scalp Acupuncture on the Walking Efficiency and Coordination Function in Elderly Patients with Ischemic Stroke [J]. Chinese Journal of Stroke, 2024, 19(8): 902-908.
[11]	WU Yuqian, ZHANG Yumei, ZANG Dawei, FAN Xiaowei, WANG Anxin, ZHANG Xiaoli, MENG Xia. Study on the Reliability, Validity, and Sensitivity of Action Research Arm Test Scale in Evaluating the Function of Hemiplegic Upper Limb and Hand in Subacute Stage Ischemic Stroke Patients [J]. Chinese Journal of Stroke, 2024, 19(8): 915-923.
[12]	MO Qiuhong, DING Xiaobo, LI Jing, ZHANG Yanbo, LI Weirong. Research on Prediction of Recurrence of Minor Ischemic Stroke Based on Interpretable Machine Learning Models [J]. Chinese Journal of Stroke, 2024, 19(8): 924-930.
[13]	LU Dan, CHEN Weiqi, WANG Yaping, DUAN Wanying, GUO Lei, WANG Ling, LIU Liping, XU Anding, WANG Yongjun, Cerebroprotection Academic Roundtable Academic Committee of Chinese Stroke Association . Scientific Statements on Brain Cytoprotection in Ischemic Stroke—A Scientific Statement from the Chinese Stroke Association [J]. Chinese Journal of Stroke, 2024, 19(8): 938-955.
[14]	LI Guangshuo, ZHAO Xingquan. Interpretation of the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023 [J]. Chinese Journal of Stroke, 2024, 19(8): 956-961.
[15]	BAI Leipeng, LUO Jie, ZHOU Sijie, HUANG Jianhui, LIANG Mingqin, ZHAO Qingshun. Interventional Thrombectomy in Patients with Acute Ischemic Stroke after Wedge Resection of Pulmonary Lobes: Two Case Reports and Literature Review [J]. Chinese Journal of Stroke, 2024, 19(8): 962-966.